Karyopharm Therapeutics (KPTI) Cost of Revenue (2019 - 2026)

Karyopharm Therapeutics (KPTI) has 6 years of Cost of Revenue data on file, last reported at $1.5 million in Q4 2025.

• Quarterly Cost of Revenue rose 13.58% year-over-year to $1.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.9 million (up 0.86% YoY) and the FY2025 annual result came in at $5.8 million, changed 0.47% from the prior year.
• Cost of Revenue declined to $1.5 million in Q4 2025, from $2.1 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $2.1 million in Q3 2025 to a low of $589000.0 in Q3 2021.
• A 5-year average of $1.2 million and a median of $1.2 million in 2024 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue jumped 121.29% — and 2023, when it sank 32.03%.
• Tracing KPTI's Cost of Revenue over 5 years: stood at $742000.0 in 2021, then jumped by 121.29% to $1.6 million in 2022, then slumped by 32.03% to $1.1 million in 2023, then gained by 14.78% to $1.3 million in 2024, then rose by 13.58% to $1.5 million in 2025.
• The last three Cost of Revenue figures came in at $1.5 million (Q4 2025), $2.1 million (Q3 2025), and $1.0 million (Q2 2025), per Business Quant data.